Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
BMS, breakthrough, cancer, docetaxel, ESMO, kantar, Keytruda, Merck, Opdivo, Roche, Tecentriq, trial
0 Comment
Roche’s PD-L1 drug has generated impressive data in second line lung cancer